Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
UltraSPECT is a medical imaging technology company that develops advanced image reconstruction software for nuclear medicine. The company's core technology, Wide-Beam Reconstruction (WBR), allows for a significant reduction in radiopharmaceutical dose or a substantial decrease in scan time while maintaining or improving image quality. Their products, including Xpress.Cardiac and Xpress/Xact.Bone, are designed to be vendor-neutral and compatible with most existing SPECT imaging systems. By optimizing clinical workflows and enhancing patient safety through reduced radiation exposure, UltraSPECT provides high-value solutions for cardiology and oncology departments.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on UltraSPECT.